Editorial: therapeutic drug monitoring for anti-TNF agents-has it all been said?

被引：1
|
作者：
Domenech, E. [1 ,2 ]
Canete, F. [1 ]
Manosa, M. [1 ,2 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Gastroenterol & Hepatol Dept, IBD Unit, Barcelona, Spain
[2] CIBEREHD, Barcelona, Spain
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2017年 / 46卷 / 11-12期
关键词：
INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; INFLIXIMAB; COMBINATION; ADALIMUMAB; INDUCTION; TRIAL;
D O I：
10.1111/apt.14350
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1113 / 1114
页数：2
相关论文
共 50 条
  • [31] Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease
    Franca, Raffaella
    Curci, Debora
    Lucafo, Marianna
    Decorti, Giuliana
    Stocco, Gabriele
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (07) : 527 - 539
  • [32] Editorial: the immunogenicity to second anti-TNF therapy (IMSAT) therapeutic drug monitoring study-defining the risk of the in-class switch
    Wilson, Aze Suzanne
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (08) : 1294 - 1295
  • [33] Real World Experience in Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Lack of Anti-Drug Antibodies to Vedolizumab and Ustekinumab Compared to Anti-TNF Agents in IBD
    Glassner, Kerri L.
    Oglat, Ayah
    Abraham, Bincy
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S342 - S343
  • [34] ARE ALL ANTI-TNF AGENTS EQUAL? RESULTS OF MERSEY BIOLOGICS AUDIT
    Barnes, T. C.
    Abernethy, V.
    RHEUMATOLOGY, 2004, 43 : 39 - 39
  • [35] Editorial: proactive anti-TNF drug monitoring in IBD--Ready for the prime time? Authors' reply
    Sethi, Sonika
    Kumar, Aditi
    Dias, Shiluka
    Blackwell, Jonathan
    Brookes, Matthew J.
    Segal, Jonathan P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (12) : 1455 - 1456
  • [36] Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques
    Bodini, Giorgia
    Demarzo, Maria Giulia
    Djahandideh, Afscin
    Ziola, Sebastiano
    Risso, Paolo
    Bertani, Lorenzo
    Baldissarro, Isabella
    Testa, Tommaso
    Marchi, Santino
    Savarino, Edoardo
    Giannini, Edoardo Giovanni
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (04) : 382 - 388
  • [37] Therapeutic drug monitoring of anti-tnf therapy in crohn's disease is mainly influenced by systemic inflammation
    Almenara de Riquer, Susana
    Egoavil Rojas, Cecilia
    Gutierrez, Ana
    Sempere, Laura
    Cameo Lorenzo, Jose Ignacio
    Gonzalez Navajas, Jose Manuel
    Frances, Ruben
    Zapater, Pedro
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 18 - 18
  • [38] The effect of anti-TNF agents on the development of drug resistance in pulmonary tuberculosis
    Lee, Jeongmi
    Hong, Yoonki
    Hong, Ji-Young
    Park, Jinkyeong
    RESPIROLOGY, 2023, 28 : 249 - 249
  • [39] COMPARISON OF DRUG DISCONTINUATION TO INEFFICACY AND ADVERSE EVENTS BETWEEN ANTI-TNF AGENTS AND 'NON-ANTI-TNF BIOLOGIC AGENTS' IN ANTI-TNF INADEQUATE RESPONDER RHEUMATOID ARTHRITIS PATIENTS
    Martin-du-Pan, S.
    Neto, D.
    Zufferey, P.
    Ciurea, A.
    Ziswiler, H.
    Gabay, C.
    Finckh, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 615 - 615
  • [40] Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients
    Du Pan, Sophie Martin
    Scherer, Almut
    Gabay, Cem
    Finckh, Axel
    ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (06) : 997 - 999
12345